

**Driver pattern identification over the gene co-expression of drug  
response in ovarian cancer by integrating high throughput genomics  
data  
(Supplementary Material)**

Xinguo Lu<sup>1</sup>, Jibo Lu<sup>1</sup>, Bo Liao<sup>1</sup>, Xing Li<sup>1</sup>, Xin Qian<sup>1</sup>, Keqin Li<sup>1,2</sup>

1) College of Computer Science and Electronic Engineering, Hunan University,  
Lushan Nan Rd., Changsha 410082, China, 2) Department of Computer  
Science, State University of New York, New Paltz, NY 12561, USA.

**S1 Table. initial modules list.**

Modules	Genes
Module1	<p>FBXO11;SLC26A6;KEL;ZBTB2;TFF1;CCBL1;SHD;F2;SCML2;THOP1;ADAR;PDE2A;NOX5;ITGB7;MYL4;RBL2;ENO3;GATA1;HBE1;PGC;ADAM23;RAB5A;APOB;NFE2L2;VGF;GALK1;TF;SPANXC;RHBG;RNF6;PGAP1;RHAG;PRH2;SERPIND1;DCT;ZNF620;DNNT;APOM;ASGR2;ZP1;KLF1;HBG1;APOA2;NCOA2;YES1;GYPC;NME4;DOT1L;CLTCL1;SERPIN1;AHSG;AMBP;SIX6;PRODH2;FGG;CGA;APOC3;HEMGN;NPTX1;SLC7A3;WNK4;KIAA1279;CES1;MLANA;RPS4Y2;C6orf141;TM4SF5;DUSP13;RBP4;PLAC4;ALAS2;ALB;JRKL;GATA3;CPNE7;ABCC2;MAGEA12;TFDP3;SOAT2;ALDOC;GDF3;WFDC2;CA5A;SERPINA7;MAGEA3;GDAP1L1;GPX2;POU5F1;ARID3A;HSPH1;DSCAM;RHOXF2B;ITIH3;PCKSK9;RPS4Y1;CTSG;CPS1;BCAS1;AFP;AZGP1;EEF1A2;SPANXD;C4BPB;SPTA1;TYR;CPLX2;TTR;COX7A1;ISLR;ITIH2;APOH;IGFBP1;DPPA4;HBG2;C1orf64;ORM1;ORM2;TXLNB;FABP7;FABP1;PRSS3;L1TD1;FGL1;AGT;HSD17B2;CSAG1;PRSS2;MYL7;UTS2;CXorf48</p>
Module2	<p>EFCAB4B;CNNM3;OTX2;PNPLA7;STAT5B;DAZ2;SHBG;APBB1;MAP1A;PTK2B;ADAMTSL5;ZBTB10;LZTR1;XYLB;MADD;DAZ1;PCBP3;COPS7A;VWF;DDX6;MED17;CORO7;SV2A;DOHH;MIXL1;EIF2AK3;FBXL18;HEPACAM;ALG12;G6PD;CCL1;S100Z;ADAD2;KCNK1;PRPF19;RND2;NTRK1;PIAS4;LIM2;MPP2;NEK4;CREB3L3;DUSP9;HS3ST4;ZNF19;BRSK2;DFNB31;FXD2;SPN;OSGIN1;PSG8;BAAT;NRIP3;LSM11;PSG4;CXorf23;F11;GNB3;IRX1;RASL10B;CNTNAP1;RIOK3;PKMYT1;CSNK1A1L;USP38;MASP2;TTY13;AADACL4;FGFR4;TTN;C5orf38;LRRC4B;CHST13;HAR1A;FAM123A;ACSM2A;CCL16;SLC22A2;FGA;HILS1;SYDE1;CLDN15;WSCD1;STRN3;GNG13;SERPINF2;GPR63;CYGB;EXOC6;ANGPTL3;RNF38;C1orf187;TPTE;CSF3;THEG;LOC283693;RSRY1;SLC8A3;EIF1AY;SLC9A5;AIFM3;CYP1A1;PKN3;ANKFN1;FSTL4;TPD52;CCR10;SPNS3;SYT3;KCNK6;ROBO4;SYN2;MEIS1;TAPT1;MDGA2;TNFSF9;PKLR;CRH;KIFC3;B4GALNT1;DDX3Y;OR5D13;GFI1B;FAM83G;PRDM9;TCEA1;RELL2;GCKR;RAB26;SLC39A5;ART4;NMNAT3;CDH9;GLYCTK;C2orf48;SMAD7;CETP;AMTN;SYNGR3;HRC;SOCS6;PAPPA;SFTPA1;CPN1;MAPK12;CORO6;HGFAC;PAX3;PBX1;SHC4;NLGN4Y;GGT6;KCNK12;LTB4R;ZDHHC22;SOX10;DLX1;CNTNAP4;TSGA10IP;MYPN;SCGB3A2;NR2E1;UPK1A;IL23R;RHD;CDH7;GLRA3;RALB;FTCD;ZNF488;APOA5;SLC5A11;NGFR;HSF4;AURKC;SLC2A2;RAET1E;RHEBL1;CCDC141;OR5111;C1orf61;SLC18A1;HYAL1;NDST4;OR1D2;PRTG;MYH2;C8B;CD34;ANKS4B;PROC;PRAMEF8;IGFBP1;SMAD4;MRGPRX3;SULT2A1;FUT5;USH1C;SMOC1;CALCR;MYOM3;PIWIL2;SYT6;SOX21;ZIM2;CYP2F1;MMRN2;KIAA1804;CACNA1H;GATA2;CDA;SERPINA4;PRODH;NOTUM;HBQ1;KLRC4;POU4F1;FSD1;TSPAN18;C3orf58;NKD1;TMEM171;PAH;PLP1;SLC30A10;MAGEB2;RLBP1;SLC17A2;PLA2G12B;XKR3;MAP2K7;SMCR5;SERPINA10;TRPV6;KRT34;F5;NOG;CLEC14A;TERT;FETUB;RAB3B;NR0B2;HAND1;IRF6;SLC38A5;CPA4;SERPINA11;SLC45A2;FAM9B;SLC30A3;GYPE;C8A;XPR1;TMEM145;SLC12A3;PTPRZ1;LCTL;BMP5;SERAC1;PRDM7;CLCA2;RNF138;WNT10B;CREG2;C8orf22;PTGFR;SULT2B1;DCX;MAPK4;KLB;HPD;MS4A3;NLRP11;CYP19A1;GALR1;ESX1;ADCY4;MYO1A;OR51B5;CDH1;SERPINA6;PRAP1;ISX;PAQR9;TRPM1;LXB2;DRD5;IGF2BP1;GCNT1;CHRNA9;PLAC2;CEACAM5;SPRR3;ADH4;SCGN;TLR5;KRTAP3-1;ARG1;KCNJ2;ACSM2B;KRTAP1-5;MIA2;XBP1;NEFM;SGPP2;DLX2;FGB;CDH4;C1orf210;SPINK4;MSMB;ABCC4;EMR1;BTLA;TFAP2B;VIL1;CPEB1;GABRB1;DQX1;NR1H4;ATP8B3;CLDN14;ALDH1A2;KCNE3;TRIM49;EFNB2;HOXC13;BLK;FGF19;NEFL;LOC</p>

	441601;NDST3;GJA4;ODAM;TSPY2;PNLIPRP2;BTBD16;POU3F2;ONECUT1;TAC3;CHIT1;TMED6;GYPB;TYRP1;EGFL6;NPPB;DNER;TUBAL3;IRX2;LYVE1;SLC6A4;FOXG1;VIT;PRDM13;LRRTM1;LGR6;C16orf73
Module3	PRKG1;OXT;MEIS3;VAT1;ILK;SLC2A14;HLX;ADAMTS16;KERA;SH3BGL3;SMPD1;MCHR1;BCAR1;NID1;VGLL3;EMP3;ELK3;KLF2;ACTC1;ALDH1B1;ID3;SLC12A4;LRRN3;EMILIN1;TFPI;ITGA5;OR7E24;ADAMTSL1;ETS1;ASGR1;CLEC3B;FHL3;GALNTL2;FAM126A;HAS1;HTR2A;XYLT1;TCP11L1;TLL1;CACNA1C;FEZ1;EHD2;CMTM3;C7orf10;CREB3L4;TPM1;PDLIM5;GPR68;CRISPLD2;SREBF1;KATNAL1;FSTL3;LATS2;RNF175;DGKI;CHSY1;PRND;MSC;TAS1R1;ZCCHC5;NKAPL;TGFB1I1;CBLN4;LIX1L;SLC22A3;F2RL2;TM4SF19;ZMAT3;SH3PXD2A;GREM2;SPOCD1;GPR1;EPHA2;IGFBP6;ELL2;TNC;EFEMP2;MGC45800;DACT3;FGF7;ACTA1;A1BG;SLC2A3;EXTL1;AQP1;RANBP3L;AKT3;ANGPTL2;SVEP1;CPNE8;CCL26;DOCK11;PMP22;NUAK1;GOLIM4;ANKRD29;THBS1;GFRA1;CNN2;PHLDA1;PPAPDC3;LMOD1;ZEB1;PSD3;FBN1;TRPA1;PLXNC1;PTRF;SLC16A7;ACAN;IGFBP4;FGF1;HSPB7;SERPINB7;FGF2;AFAP1;RBMS3;ENPP1;GRID1;GADD45B;MFS D4;DFNA5;RCAN1;AOC3;BDKRB1;PLXDC1;STX2;FOXF1;PTGER3;PROCR;COL8A1;ANTXR1;AK5;GALNT5;ECM1;OLFML3;RGS17;GNG11;TIAM2;SNAI1;DNAJB5;TGM2;TGFB I;APCDD1;VEGFC;GFPT2;PCOLCE;ANGPTL7;SPHK1;PDGFRA;ETV1;C16orf45;ZNF365;NBL1;TPM2;MEOX2;ODZ3;ISL1;ZNF215;PRKD1;COPZ2;PDZRN4;BACH2;RNF128;GAP43;FSTL1;NCAM2;THY1;HAND2;ADAMTSL3;LRRRC15;MAF;F2R;BMP4;PHLDB2;GHR;DEPDC7;CDH13;BASP1;PLAC9;FLNC;SPOCK1;BNC2;BAI3;BMP2;SEMA3C;SEMA3D;AEBP1;KCNE4;NT5E;TNFSF4;JAM2;TAGLN;ACTA2;NEXN;LSAMP;RGS16;PRRX1;TWIST1;VDR;ZFH4;HAS2;ST8SIA1;PDLIM3;CLSTN2;MXRA5;TMEM45A;CCDC80;SERPINE1;CNTN4;ADAM12;CDR1;GREM1;COL5A1;COL24A1;TIMP3;OMD;TPBG;EFEMP1;GDF6;GEM;NUDT11;SERPINF1;PLN;SALL4;CHRNA3;RGS2;OSR2;TBX18;DPT;FN1;IGF1;HS3ST2;EBF3;NUDT10;MAGEL2;ACTG2;ITGA11;ANGPTL1;SORCS2;STMN2;C1QTNF3;PDPN;PLAU;MFAP2;PEPF1;CH25H;MFAP4;MOXD1;CNN1;GAS1;SCG2;DSC3;COL5A2;BCHE;DKK1;CALB2;CILP;VCAN;CDH11;NDN;PDE1A;PPAPDC1A;DCN;ALPK2;SFRP1;CTHRC1;CCL11;SCRG1;COMP;LUM;HSPB3;ZNF521;INHBA;PTGIS;NNMT;THBS2;ITGBL1;GJB2;OGN;ASPN;SFRP4;IGFL2;LIX1;FAP;SFRP2;COL11A1;POSTN
Module4	ATPAF2;FOXD4L1;GNG8;BTN2A1;CNIH2;PRKDC;OAZ2;MCAT;RFNG;HMG20B;GOLGA4;GOLGB1;PRKAR1B;TAOK2;PIP5K1C;ZRANB1;ERIGC2;FAM96B;CLDN17;DDX28;BSG;POLRMT;ARL2;NAPB;FAM43B;C19orf24;NDOR1;LDB1;TXNL4A;SPIRE2;WDR18;KLF14;FAM108A1;ATP9B;CEP192;ZNF131;NCL;ZNF391;YIPF3;PROKR1;HBM;UXS1;MAP3K4;KCNAB3;DIRAS1;C10orf137;MKNK2;BCL7C;MEX3C;HNF1A;NDUFS7;FGF22;PFKL;LMAN1;KLF16;IL17RC;SYNGR4;NUP153;SS18;FOXC2;PASK;CFDP1;ALDH5A1;FAM70B;TRIP12;ZNF182;SACS;PIGW;UTF1;ZNF135;ABCA7;ZNF784;IRX4;SF3A2;AMMECR1;PHKA1;C21orf56;SOX17;SOX8;PGF;GRIN2C;SPPL2B;ZNF75A;CHORDC1;P2RY4;SNX8;HCN2;SLC34A3;ISOC1;PFKFB4;TLX2;IAPP;ATAD3C;GNG7;FUS;TCEAL3;HNRNPA2B1;TCEAL6;MGC45922;FOX1;UCN;LIN7B;SLC4A8;HIRA;SLC22A18;ADRBK2;RNF145;TEPP;FBXL8;ITGB1BP3;CREBZF;CADM3;KCNMB3;FAIM3;AFG3L2;GPR151;KISS1R;SLC39A6;PGRMC1;MMP17;TM9SF2;ELMO3;GPR78;DOCK9;HAGHL;GPR20;PARD6A;MAFA;TCEAL5;ZSCAN10;CACNA1E;GAMT;GALNT9;LTC4S;AMH;HES7;C16orf74;FOX1;HRK;CRYAB;HIST1H4L;NRN1;CMBL;SCGB3A1;ADAMTS1
Module5	FBXO11;SLC26A6;KEL;ZBTB2;TFF1;CCBL1;SHD;F2;SCML2;THOP1;ADAR;PDE2A;NOX

	5;ITGB7;MYL4;RBL2;ENO3;GATA1;HBE1;PGC;ADAM23;RAB5A;APOB;NFE2L2;VGF;GALK1;TF;SPANXC;RHBG;RNF6;PGAP1;RHAG;PRH2;SERPIND1;DCT;ZNF620;DNNT;APOM;ASGR2;ZP1;KLF1;HBG1;APOA2;NCOA2;YES1;GYPC;NME4;DOT1L;CLTCL1;SERPIN1;AHSG;AMBP;SIX6;PRODH2;FGG;CGA;APOC3;HEMGN;NPTX1;SLC7A3;WNK4;KIAA1279;CES1;MLANA;RPS4Y2;C6orf141;TM4SF5;DUSP13;RBP4;PLAC4;ALAS2;ALB;JRKL;GATA3;CPNE7;ABCC2;MAGEA12;TFDP3;SOAT2;ALDOC;GDF3;WFDC2;CA5A;SERPINA7;MAGEA3;GDAP1L1;GPX2;POU5F1;ARID3A;HSPH1;DSCAM;RHOXF2B;ITIH3;PCSK9;RPS4Y1;CTSG;CPS1;BCAS1;AFP;AZGP1;EEF1A2;SPANXD;C4BPB;SPTA1;TYR;CPLX2;TTR;COX7A1;ISLR;ITIH2;APOH;IGFBP1;DPPA4;HBG2;C1orf64;ORM1;ORM2;TXLNB;FABP7;FABP1;PRSS3;L1TD1;FGL1;AGT;HSD17B2;CSAG1;PRSS2;MYL7;UTS2;CXorf48
Module6	NLRC5;CD226;PIK3CD;PPM1M;FCRL3;C7orf41;SH2B3;P2RX7;COTL1;RPS27L;CACNA2D4;CATSPER1;LAT2;CCL23;TNFRSF10C;BMP2K;HERPUD1;MYO5A;GPR114;EBI3;PFKM;DPEP2;LILRA2;KIAA0513;HGF;TNFSF12;IRF8;APOL4;CORO1A;CLEC7A;CD274;LGALS9;GAB3;HAMP;BTN3A3;LGALS12;TDRD7;SEMA6C;LILRB1;RAC2;APOC2;RAB32;PSMB10;CYB5R4;CSF1R;CCL3;LAX1;CHRNA6;GNG12;DENND1C;IL32;PAG1;PLEK2;CECR6;SPECC1;GNB4;MEF2C;ARRDC2;LY86;PTPRO;CD302;BTK;STAT1;RNASE2;IL21R;CD86;SNX10;CD33;ARNT2;HMHA1;OLR1;PNMT;VAV1;CCL4;CCL17;RNASE6;CCDC109B;VMO1;KCTD12;IGSF21;APBB1IP;CFD;FXD1;SAMSN1;EVI2B;FCGBP;CX3CR1;LY96;ANPEP;TPK1;APOC1;DAPP1;HLA-DQA1;CCL2;HLA-DQA2;IL18;FBXO32;BATF2;TNFSF10;CCL5;DDX25;EVI2A;DHRS9;CLEC2B;CCL8;IL15;GPX3;IL7;CCL18;GBP3;C10orf82;CD38;C3;CCL7;CCL13
Module7	ZNHIT3;ANKRD23;CENPT;ACTL6A;FXR1;DNAJC19;C6orf120;UNKL;MRPL47;OPA1;UBE2F;MUSTN1;PIK3CA;MFN1;SPCS2;MAD2L1BP;ZNF639;GMPS;C5orf22;LCAT;KPNA4;YIPF6;SENP2;RAB2A;RAB1A;ACSL3;DNAJB11;SLC33A1;PARL;WDFY1;ACVR1;TBL1XR1;GFM1;FNDC3B;SELS;NDUFA10;IER3IP1;SMC4;MYNN;RQCD1;MAGEF1;IMPAD1;NDUFB5;SERP1;TM2D3;PHACTR4;SSR1;PDCD10;PANK3;C3orf33;ZFH3;ARPM1;UBE2E1;TMEM30A;AP1S3;ECT2;B3GALNT1;EID3;MAGEH1;SERPINI1;FRK;GPR160
Module8	C1orf201;CCDC104;CCDC113;LRRC27;C11orf74;HYDIN;TNFAIP8L1;C16orf48;ARL6;TEKT4;RFX2;WDR54;NEK10;GAS2L2;TEKT3;C1orf173;C22orf15;EFCAB2;CPXCR1;DUOX1;MNS1;DYX1C1;KCNE1;CACNG6;LRRC34;DNAH2;C8orf34;IQUB;CCDC17;LRRC46;RSPH10B;TSNAXIP1;TRIM55;LRRC48;CCDC89;CCDC135;DNAH10;ZNF214;STK33;WDR49;MEIG1;C10orf107;CCDC65;NME5;FAM92B;CXorf41;RGS22;TPPP3;SPATA4;C11orf70;C15orf26;ARMC4;C1orf114;AKAP14;WDR16;SRD5A2;C1orf87;DYNLRB2;TTC29;WDR69;ARMC3
Module9	PRKCG;RPL23;FAM138F;RPL19;COPB2;HSPA5;MRTO4;AARS;CCL24;HGSNAT;DYNC1L2;PFDN5;NBP15;TUG1;F11R;MRPL45;DAZAP2;EHMT1;ZNF593;AP3D1;NLE1;GLG1;RPL12;HHLA1;RPS15;OMP;UBC;LCE3A;HSP90B1;TAS2R9;MED1;RPL23A;RPL6;LASP1;RPL32;MRPL1;NTHL1;RPL36A;ATP5D;MRPL54;RPL27;HABP4;RPS21;RPS15A;RPL38;RPS7;SEMA4D;GPHB5;LIAS;AFMID;DDR1;OR10A7;RPL31;NPM3;RPL36;RPL34;CHD3;PDHA1;RPL29;RPL24;STARD9;ANKRD2;TOMM7;CDKL3;RPL35A;BEST4;HSD11B1L;SPAM1;TLE1;HMGCS1;RPS18;RPL39;RPS3A;SLC27A5;SOX4;SHROOM2;TAF15;ZNF556
Module10	PSMD6;KIAA2026;CBWD5;EXOSC3;CBWD6;ARPC5L;ATP6V1G1;UBAP2;CDC37L1;SM

	C5;GLRX5;FAM122A;C9orf64;ZDHC21;FUNDC1;GINS3;KIAA0020;RBBP7;CBWD1;PAPDC2;DNAJA1;USP1;PIA1;RMI1;C9orf82;ERMP1;MTM1;NFIB;VLDLR
Module11	PER1;PPP1R15A;RHOB;KLF4;KLF6;NR4A1;EREG;JUNB;HBA2;NR4A3;CTGF;ATF3;HBD;DUSP1;ZFP36;CYR61;FOSB;FOS;EGR3;EGR1;IL6;EGR2;AREG
Module12	HSP90AB1;CTNBL1;PSPC1;SMARCA1;TRADD;RSAD1;CKLF;CPNE1;WDR35;MT1X;PALM;MT2A;ASPHD1;MT1B;MT1G;MT1JP;LGALS2;MT1H;MT1M;MT1E;TFPI2
Module13	TAF12;POLR2E;AKR7A2;LDLRAP1;CDC34;AKR7A3;RGS19;RPS6KA1;AP1S1;CASP9;ARFRP1;TNIP2;HMGCL;ALDH4A1;WASF2;LYPLA2;TRAF7;RPL11;NOC2L;PABPC4;C1orf38
Module14	PRKRA;GGPS1;RBM34;DUSP12;C1orf131;FH;EGLN1;TOMM20;EXOC8;CD46;C1orf31;ZBTB7A;ARID4B;SCCPDH;CPOX;ADSS;TAF5L;ACBD3;TTC13;SRP9
Module15	LYL1;MYO1G;ZAP70;GZMM;GNA15;SCO2;MATK;MFNG;KLRK1;CD8B;RAB33A;CD3D;CBFA2T3;BCL11B;KLRC2;KLRD1;KLRC3
Module16	IL1F10;WDR87;PIK3R5;OR4S1;MYH8;SLC10A1;PPM1F;SPZ1;ARHGAP22;VPS18;ZCHC13;CABP7;PCSK4;TEX12;CGB1;C9orf47
Module17	CHAF1A;YIF1B;CCNF;WDR62;MXD3;BCL2L12;PPIH;LMNB2;GTSE1;AURKB;CENPO;CDC20;GINS4;MGC21881;C1orf135;ZYG11A
Module18	BTBD2;GNA11;MAP2K2;DCTN1;PNPLA6;GTF2F1;ZNF358;PLD2;DUS3L;TRIP10;CBX6;NFIC;EEF2;MAN2B1;TIMM44;SH2D3A
Module19	ZNF707;PHF20L1;ZNF34;FAM91A1;HSF1;PUF60;ZNF7;CHRAC1;ZNF16;EXOSC4;SCRIB;TIGD5;PTP4A3;SQLE;C8orf51
Module20	ARMC6;FBXO24;TMEM161A;PGPEP1;CCDC124;DDX49;MAST3;UBA52;FAM125A;STX10;C19orf60;C19orf44;FBXW9;MAST1;RPL18A
Module21	JTB;UBFD1;FDPS;PEX19;FDPSL2A;PIGM;KARS;ATP6V0D1;ADAT1;MLYCD;SYNPO2L;ZNF689;CCNDBP1;PANK1
Module22	RIN1;SERPINA1;ST3GAL1;CHI3L2;CYP24A1;VNN1;SAA4;HP;LRG1;PI3;SAA2;S100A9;SAA1;HPR
Module23	MAGEA5;SSX5;SSX3;DSCR4;SSX2;SSX1;SSX7;MAGEA1;MAGEA10;MAGEA8;MAGEA11;DSCR8;MAGEA9
Module24	CAMK1G;SLC4A4;WFDC1;PCSK6;GREB1;RBP7;LAMA2;GATM;CCDC48;DLK1;WNT2B;FOXL2;TSPAN8
Module25	EXOSC9;IDH2;SNRPA1;POLG;FANCI;CENPE;GINS2;RAD51;DIAPH3;MND1;NEIL3;GGH;NMU
Module26	CCL15;MRAP;SCARA5;PI16;ASPA;ADH1B;PPARG;CD36;SV2B;PLA2G2A;TIMP4;FABP4
Module27	KRT80;KRT5;ANXA8L2;KRT6C;TGM1;KRT6B;GPR87;KRT6A
Module28	HIST1H3A;SH3BP5L;H3F3A;RAB3GAP2;MIA3;B3GALNT2;PARP1;MCM3
Module29	POLR3A;AKT1S1;RPL18;RPS11;RPL13A;RPL26;C17orf48;RPS24
Module30	SAMD10;CRCT1;KRTAP5-8;MAB21L2;DIRC1;PRSS36;IL27
Module31	HOXB4;HOXB7;HOXB3;HOXB5;HOXB2;HOXB8;HOXB6
Module32	SERGEF;GNB2L1;EIF3F;IPO7;RPS13;RPLP2;RPL27A
Module33	UGT2B4;UGT2A3;UGT2B10;CD200;UGT2B11;UGT2B7
Module34	PAGE1;COX7B2;PAGE5;MAGEC1;PAGE2;MAGEC2
Module35	ANKRD27;C19orf40;POP4;C19orf12;CCNE1;CDKN2A

Module36	HOXA2;HOXA7;HOXA5;HOXA9;HOXA4
Module37	CD1B;CD1E;CD1C;S100B;CD1A
Module38	SNAPC2;TRAPPC5;NDUFA7;CD320;RPS28
Module39	SUPT16H;APEX1;METTL3;DAD1;PARP2
Module40	PCDHB15;PCDHB14;PCDHB8;PCDHB16;PCDHB5

**S2 Table. List of initial modulators for the mutation genes.**

<p>GOLIM4;KCNMB2;MRPL47;CCDC39;SERPINI1;WDR49;LOC646168;EGFEM1P;TNFSF10;MECOM;ECT2;SPATA16;NLGN1;TBL1XR1;ZMAT3;PIK3CA;ZNF639;USP13;PEX5L;PDCD10;MIR551B;MYNN;LRRC34;LRR1Q4;TERC;LRRC31;ARPM1;LOC100128164;SAMD7;GHSR;NAALADL2-AS3;MIR4789;KCNMB3;MFN1;GNB4;ACTL6A;NDUF5;TTC14;DNAJC19;FXR1;ASAP1;KCNQ3;PVT1;ADCY8;OC90;PHF20L1;TG;ST3GAL1;ZFAT;KHDRBS3;POU5F1B;LOC727677;MYC;MIR1204;MIR1205;MIR1207;MIR1206;MIR1208;LOC728724;GSDMC;EFR3A;HHLA1;LRRC6;HPYR1;TMEM71;NDRG1;ZFAT-AS1;MIR30B;MIR30D;LOC286094;FLJ43860;GPAA1;TCEA1;FBXO11;ARMC4;ZNF20;ZNF707;CDCA8;FARSA;ADCK5;ZNF527;TRPC4AP;JRKL;SDHA;ENDOD1;YTHDF3;LAPTM4A;FBXL6;WISP1;SLA;STK3;FAM91A1;EED;IFT52;ZNF345;ARFGAP1;TIGD5;HSF1;SAMD9L;FAM66E;DEFB103A;SPAG11B;DEFB103B;DEFB4B;SPAG11A;DEFB4A;LOC100132396;BANP;JPH3;ZCCHC14;KLHDC4;MYH10;STX8;SRCIN1;ACACA;LINC00324;NTN1;GAS7;USP43;MYH13;MYH4;HS3ST3A1;ADORA2B;KSR1;KRT18P55;RAD51L3-RFFL;CCL23;AP2B1;GAS2L2;SLFN11;MYO19;AATF;SYNRG;TADA2A;FBXL20;LOC100131347;CWC25;PLXDC1;FBXO47;PSMD3;WIPF2;ERBB2;IKZF3;ALOX15B;ALOX12B;GUCY2D;MIR4314;PER1;ALOXE3;TMEM107;AURKB;VAMP2;MIR3676;C17orf59;MIR4521;RANGRF;ARHGEF15;PFAS;ODF4;SLC25A35;CTC1;RPL26;KRBA2;NDEL1;LOC100128288;RNF222;CCDC42;MFSD6L;SPDYE4;PIK3R6;DHRS7C;RCVRN;GLP2R;MYH8;MYH1;CDRT15P2;MEIS3P1;TBC1D26;ZSWIM7;UBB;SMCR5;C17orf51;WSB1;MIR4522;TBC1D3P5;LGALS9;NOS2;PPY2;CCL7;CCL2;CCL8;CCL13;TMEM132E;C17orf102;ZNF830;CCT6B;RFFL;LIG3;SLC35G3;RAD51D;UNC45B;FNDC8;NLE1;SLFN5;SLFN13;SLFN12;SLFN12L;PEX12;SLFN14;SNORD7;RASL10B;C17orf50;TAF15;MMP28;C17orf66;CCL14;CCL15;RDM1;CCL14-CCL15;LYZL6;CCL3;CCL18;CCL3L1;CCL3L3;CCL4L2;CCL4L1;TBC1D3C;TBC1D3B;TBC1D3H;ZNHIT3;TBC1D3G;GGNBP2;PIGW;DHRS11;MRM1;LHX1;MIR2909;C17orf78;DUSP14;DDX52;TBC1D3F;LOC284100;TBC1D3;LOC40434;MRPL45;SOCS7;GPR179;ARHGAP23;C17orf96;PIP4K2B;PCGF2;PSMB3;CISD3;MIR4734;MIR4726;MLLT6;RPL23;SNORA21;LASP1;C17orf98;LOC100505576;MIR4727;FLJ43826;CACNB1;ARL5C;STAC2;RPL19;MED1;CDK12;STARD3;PPP1R1B;NEUROD2;PGAP3;PNMT;TCAP;MIEN1;MIR4728;GSDMB;LRRC3C;ZBPB2;GSDMA;ORMDL3;SNORD124;THRA;MED24;CSF3;NR1D1;MSL1;CASC3;RAPGEFL1;RARA;GJD3;CDC6;ANKRD24;GNA15;IZUMO4;ABCA7;RNF126;KISS1R;REXO1;CSNK1G2;DOT1L;TLE2;GNG7;CELF5;MFSD12;NFIC;ZBTB7A;MATK;STAP2;PLIN3;UBXN6;DPP9;THEG;PPAP2C;MIER2;TPGS1;ODF3L2;C2CD4C;MADCAM1;SHC2;GZMM;POLRMT;CDC34;BSG;HCN2;FGF22;PALM;C19orf21;PRSS57;FSTL3;PTBP1;AZU1;MED16;PRTN3;CFD;MIR3187;ELANE;LPPR3;MIR4745;R3HDM4;C19orf6;WDR18;CNN2;GRIN3B;ARID3A;HMHA1;SBNO2;POLR2E;GPX4;EFNA2;CIRBP;ATP5D;C19orf24;C19orf26;STK11;MIDN;CIRBP-AS1;MUM1;NDUFS7;DAZAP1;GAMT;RPS15;REEP6;PCSK4;MEX3D;C19orf25;PLK5;APC2;ADAMTSL5;TCF3;UQCR11;MBD3;ATP8B3;MIR1909;LOC100288123;ONECUT3;CSNK1G2-AS1;SCAMP4;ADAT3;MKNK2;MOB3A;BTBD2;AP3D1;C19orf35;JSRP1;PLEKHJ1;SPPL2B;MIR4321;OAZ1;LSM7;AMH;MIR1227;LINGO3;TIMM13;GADD45B;LMNB2;TMPRSS9;SLC39A3;DIRAS1;ZNF555;THOP1;SGTA;ZNF554;ZNF556;TLE6;ZNF57;ZNF77;GNA11;AES;S1PR4;NCLN;FZR1;DOHH;C19orf77;C19orf71;GIPC3;HMG20B;TBXA2R;C19orf29-AS1;TJP3;APBA3;MRPL54;RAX2;ZFR2;ATCAY;EEF2;PIAS4;SNORD37;MIR637;DAPK3;ITGB1BP3;CREB3L3;SIRT6;MAP2K2;EBI3;FSD1;SHD;T</p>
--

MIGD2;CCDC94;SH3GL1;MPND;CHAF1A;MIR4746;PLIN4;LRG1;HDGFRP2;SEMA6B;PLIN5;C19orf10;TNFAIP8L1;LOC100131094;MIR7-3HG;TICAM1;FEM1A;MIR7-3;LOC100128946;XPNPEP3;FAM19A5;NFATC3;LOC283867;TMC07;PLA2G15;CDH1;SMPD3;ESRP2;SLC7A6;PRMT7;SLC7A6OS;HAS3;GGA1;TMEM184B;PLA2G6;TRIOBP;EIF3L;CBY1;DMC1;CACNA1I;CYTH4;ELFN2;CARD10;LGALS2;CDC42EP1;SH3BP1;LGALS1;NOL12;PDXP;ANKRD54;GCAT;MIR659;MIR658;H1F0;POLR2F;MICALL1;C22orf23;MIR4534;PICK1;BAIAP2L2;SLC16A8;MAFF;LOC400927;DDX17;KCNJ4;KDEL3;LOC646851;DNAL4;SUN2;GTPBP1;TOMM22;JOSD1;NPTXR;CBX6;APOBEC3B;APOBEC3A;APOBEC3C;APOBEC3D;APOBEC3F;CBX7;APOBEC3G;MGAT3;ATF4;SMCR7L;RPS19BP1;MYH2;SOX10;SLC12A3;FAM120B;PPP2R2A;LONP1;CAMK2D;CSNK1E;ASS1;GALR3;APOBEC3H;RB1;CCDC135;MFNG;C9orf82;SOSTDC1;RRM1;MT1M;SLC18A1;EIF4G3;XRCC4;KLF16;APOL6;PIP5K1C;WDR16;CCL1;VPS33B;LOXL2;FAM108C1;HPS4;C19orf29;DNAJC16;C1orf172;FGL1;TOP2A;GRB7;USP48;UBE4B;ZCCH9;SCAMP1;ZDHC21;RAB28;MSR1;CCL16;FAM108A1;CCL11;DOK2;CCL4;HES7;CCL5;DHRS4;MDN1;HIATL1;PIK3R5;HNF1B;NUP43;TCP1;C6orf120;ZNF500;SF3A2;PIWIL2;APOB;BRCA1;BRCA2;COL6A6;CSMD3;DNAH3;DNAH8;FLG2;HSPG2;HUWE1;KIAA1109;ODZ1;RZR2;SLCO1C1;STAB2;SYNE2;ZFHX4;NEB;RB1CC1;SCN8A;CREBBP;DST;FAT3;FLG;HMCN1;LRP1B;LRP2;MUC17;NF1;PTPRZ1;SORCS3;SPTB;TP53;TTN;UBR4;MT-ND4;USH2A;HYDIN;RYR1;MUC16;


**S3 Table. Modulator gene list after module network learning.**

Modulator gene list							
MT1M	GOLIM4	C1orf172	AATF	LMNB2	C19orf24	LRRC31	RPS15
LASP1	JPH3	ADAMTSL5	MYC	PALM	TNFSF10	HMG20B	SOSTDC1
AMH	SLC18A1	HES7	C6orf120	FAM108A1	TIGD5	TLE2	WSB1
HNF1B	UBE4B	MRPL47	POLRMT	FAM91A1	SOX10	FBXO11	KLF16
PHF20L1	SLFN13	MYH2	CDC34	MED24	TBL1XR1	MFNG	MYH8
ARPM1	CCL11	HHLA1	NDUFB5	FGL1	DOT1L	MRM1	MRPL54
FSTL3	PIK3R5	CNN2	C9orf82	SBNO2	CCL8	ZNF707	CCL7
PDCD10	CCL5	GNA11	CCL4	KISS1R	KCNMB3	POLR2E	MFN1
FSD1	ECT2	CCL18	GAS2L2	CCL16	FGF22	RPL19	WDR16
SLC12A3	CCL23	C19orf10	RCVRN	SF3A2	GADD45B	RASL10B	WDR18
CCDC135	EEF2	PLXDC1	ARHGAP23	GZMM	LRG1	PPP1R1B	TCAP
BRCA1	HYDIN	APOB	MUC16	ZFHX4			


**S4 Fig. List of dosage-sensitive and dosage-resistant genes and the scatter diagrams of these genes.** We applied a local polynomial regression fitting model with the R package loess to the scatter diagram for 93 regulatory genes with 324 samples. DS threshold is set to (-0.25,0.25) as the filtering criteria for dosage-sensitive genes(DSGs) and the others were selected as dosage-resistant genes(DRGs). Therefore, we obtained 44 DSGs and 49 DRGs (see Supplementary Fig. S4). The LRG1, HYDIN, POLRMT and TNFSF10 gene data scatter diagram for CNVs or somatic mutations vs. Gene expression with local polynomial regression fitting model are shown in Fig. 3 in our main manuscript, in which HYDIN is derived from somatic mutations. Each red point represents an independent sample, the black line is the linear regression result, and the blue curve is the local polynomial regression fitting result. In Fig. 3A and Fig. 3B the slope of the black lines are close to 0, so the dosage sensitivity score are nearly equal to 0. In Fig. 3C and Fig. 3D the

slope's absolute value of the black line are above 1, the blue curves are mostly overlapped with the black line, so the dosage sensitivity score are above 1. It can be concluded from the graph that the genes for Fig. 3A and Fig. 3B are dosage-resistant genes, whereas the genes for Fig. 3C and Fig. 3D are dosage-sensitive genes. Here, we list another 10 scatter diagrams(related gene list: ADAMTSL5, APOB, ARHGAP23, ARPM1, AZU1, BRCA1, C19orf10, C19orf24, C1orf172 and C6orf120) of these 93 genes.

**Relationship between gene expression & CNV**




**Relationship between gene expression & SM**







**Relationship between gene expression & CNV**




**Relationship between gene expression & CNV**




**Relationship between gene expression & cnv**




**Relationship between gene expression & SM**




**Relationship between gene expression & CNV**




**Relationship between gene expression & CNV**



**Relationship between gene expression & CNV**



**Relationship between gene expression & CNV**



**S5 Table. The GO term pathways enriched by DRGs.**

Pathway ID	Description	Gene Ratio	BgRatio	pvalue	p. adjust	qvalue	geneID	Count
G0:0048247	lymphocyte chemotaxis	6/40	55/16672	3.43E-09	2.51E-06	2.12E-06	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/ CCL5	6
G0:0002548	monocyte chemotaxis	6/40	58/16672	4.76E-09	2.51E-06	2.12E-06	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/ CCL5	6
G0:007	mononu	6/40	73/166	1.95E-	6.86E-	5.80E-	CCL11/	6

1674	clear cell migration		72	08	06	06	CCL16/ CCL18/ CCL23/ CCL8/C CL5	
G0:007 0098	chemokine-mediated signaling pathway	6/40	80/166 72	3.40E- 08	6.95E- 06	5.87E- 06	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/C CL5	6
G0:007 2676	lymphocyte migration	6/40	81/166 72	3.67E- 08	6.95E- 06	5.87E- 06	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/C CL5	6
G0:003 0593	neutrophil chemotaxis	6/40	82/166 72	3.95E- 08	6.95E- 06	5.87E- 06	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/C CL5	6
G0:007 1347	cellular response to interleukin-1	6/40	85/166 72	4.91E- 08	7.40E- 06	6.25E- 06	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/C CL5	6
G0:199 0266	neutrophil migration	6/40	88/166 72	6.05E- 08	7.40E- 06	6.25E- 06	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/C CL5	6
G0:009 7529	myeloid leukocyte migration	7/40	151/16 672	6.31E- 08	7.40E- 06	6.25E- 06	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/C CL5/AZ U1	7

G0:007 1621	granulocyte chemotaxis	6/40	97/16672	1.09E-07	1.11E-05	9.41E-06	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/ CL5	6
G0:007 1356	cellular response to tumor necrosis factor	8/40	250/16672	1.16E-07	1.11E-05	9.41E-06	APOB/ CL11/ CL16/ CL18/ CL23/ CL8/ CCL5/ BRC A1	8
G0:009 7530	granulocyte migration	6/40	106/16672	1.84E-07	1.61E-05	1.36E-05	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/ CL5	6
G0:003 4612	response to tumor necrosis factor	8/40	268/16672	1.98E-07	1.61E-05	1.36E-05	APOB/ CL11/ CL16/ CL18/ CL23/ CL8/ CCL5/ BRC A1	8
G0:007 0555	response to interleukin-1	6/40	110/16672	2.30E-07	1.65E-05	1.40E-05	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/ CL5	6
G0:003 0595	leukocyte chemotaxis	7/40	183/16672	2.35E-07	1.65E-05	1.40E-05	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/ CL5/ AZ U1	7
G0:005 0729	positive regula	6/40	115/16672	2.99E-07	1.98E-05	1.67E-05	CCL11/ CCL16/ CCL18/	6

	tion of inflammatory response						CCL23/CCL8/CL5	
G0:0071346	cellular response to interferon-gamma	6/40	138/16672	8.78E-07	5.46E-05	4.61E-05	CCL11/CCL16/CCL18/CCL23/CCL8/CL5	6
G0:0060326	cell chemotaxis	7/40	240/16672	1.46E-06	8.56E-05	7.23E-05	CCL11/CCL16/CCL18/CCL23/CCL8/CL5/AZU1	7
G0:0050900	leukocyte migration	8/40	362/16672	1.92E-06	0.000106108	8.96E-05	APOB/CL11/CL16/CL18/CL23/CL8/CC L5/AZU1	8
G0:0034341	response to interferon-gamma	6/40	159/16672	2.01E-06	0.000106108	8.96E-05	CCL11/CCL16/CCL18/CCL23/CCL8/CL5	6
G0:0032103	positive regulation of response to external stimulus	7/40	261/16672	2.55E-06	0.000128219	0.000108255	CCL11/CCL16/CCL18/CCL23/CCL8/CL5/AZU1	7
G0:007	positi	6/40	170/16672	2.96E-	0.0001	0.0001	CCL11/	6

0374	ve regula tion of ERK1 and ERK2 cascad e		672	06	42233	20087	CCL16/ CCL18/ CCL23/ CCL8/C CL5	
GO:007 0372	regula tion of ERK1 and ERK2 cascad e	6/40	237/16 672	1.98E- 05	0.0009 10875	0.0007 6905	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/C CL5	6
GO:007 0371	ERK1 and ERK2 cascad e	6/40	251/16 672	2.74E- 05	0.0012 06168	0.0010 18366	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/C CL5	6
GO:005 0727	regula tion of inflam matory respon se	6/40	295/16 672	6.75E- 05	0.0028 50541	0.0024 06707	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/C CL5	6
GO:005 0918	positi ve chemot axis	3/40	52/166 72	0.0002 60624	0.0105 85327	0.0089 37173	CCL16/ CCL5/A ZU1	3
GO:004 8245	eosino phil chemot axis	2/40	11/166 72	0.0003 04507	0.0119 09597	0.0100 55252	CCL11/ CCL5	2
GO:003 1349	positi ve regula tion of defens e respon se	6/40	396/16 672	0.0003 34988	0.0126 3385	0.0106 66738	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/C CL5	6
GO:007	eosino	2/40	15/166	0.0005	0.0210	0.0177	CCL11/	2

2677	phil migrat ion		72	77811	40279	64271	CCL5	
G0:000 9615	respon se to virus	5/40	304/16 672	0.0007 60625	0.0267 7399	0.0226 05232	APOB/C CL11/C CL8/CC L5/AZU 1	5
G0:004 3410	positi ve regula tion of MAPK cascad e	6/40	471/16 672	0.0008 36228	0.0284 85689	0.0240 50418	CCL11/ CCL16/ CCL18/ CCL23/ CCL8/C CL5	6
G0:000 2544	chroni c inflam matory respon se	2/40	22/166 72	0.0012 57754	0.0415 05871	0.0350 43334	CCL11/ CCL5	2
G0:004 8246	macrop hage chemot axis	2/40	26/166 72	0.0017 58868	0.0562 83782	0.0475 20299	CCL5/A ZU1	2
G0:000 6874	cellul ar calciu m ion homeos tasis	5/40	370/16 672	0.0018 20676	0.0565 4805	0.0477 43419	CCL11/ CCL23/ CCL8/C CL5/JP H3	5
G0:005 5074	calciu m ion homeos tasis	5/40	383/16 672	0.0021 17117	0.0638 7644	0.0539 30766	CCL11/ CCL23/ CCL8/C CL5/JP H3	5
G0:007 2503	cellul ar divale nt inorga nic cation homeos	5/40	395/16 672	0.0024 2086	0.0710 11885	0.0599 5521	CCL11/ CCL23/ CCL8/C CL5/JP H3	5



	tasis							
G0:004 5766	positive regulation of angiogenesis	3/40	120/16672	0.002958989	0.083262848	0.070298676	CCL11/LRG1/B RCA1	3
G0:007 2507	divalent inorganic cation homeostasis	5/40	415/16672	0.002996201	0.083262848	0.070298676	CCL11/ CCL23/ CCL8/C CL5/JP H3	5

**S6 Table. The GO term pathways enriched by DSGs.**

Pathway ID	Description	Gene Ratio	BgRatio	pvalue	p.adjust	qvalue	geneID	Count
G0:000 7212	dopamine receptor signaling pathway	4/43	37/16672	2.38E-06	0.002402473	0.001887291	PALM/G NA15/G NA11/K LF16	4
G0:000 3009	skeletal muscle contraction	3/43	38/16672	0.000126592	0.041598317	0.032678037	EEF2/T CAP/MY H8	3
G0:005 0879	multicellular organismal movement	3/43	47/16672	0.000239423	0.041598317	0.032678037	EEF2/T CAP/MY H8	3
G0:005 0881	musculoskeletal movement	3/43	47/16672	0.000239423	0.041598317	0.032678037	EEF2/T CAP/MY H8	3
G0:006	trabec	3/43	48/16672	0.0002	0.0415	0.0326	MED1/S	3

1383	ulamorphogenesis		72	54926	98317	78037	BN02/UBE4B	
G0:0006352	DNA-templated transcription, initiation	5/43	228/16672	0.000288531	0.041598317	0.032678037	MED1/MED16/POLR2E/MED24/POLRMT	5
G0:0060158	phospholipase C-activating dopamine receptor signaling pathway	2/43	10/16672	0.000288591	0.041598317	0.032678037	GNA15/GNA11	2
G0:0035747	natural killer cell chemotaxis	2/43	11/16672	0.000352145	0.044414239	0.034890117	CCL7/CCL4	2
G0:0010839	negative regulation of keratinocyte proliferation	2/43	13/16672	0.000497771	0.048427142	0.0380425	MED1/KDF1	2
G0:0030521	androgen receptor	3/43	62/16672	0.0005436	0.048427142	0.0380425	MED1/MED16/MED24	3

	signal ing pathwa y							
G0:005 5008	cardia c muscle tissue morpho genesi s	3/43	62/166 72	0.0005 436	0.0484 27142	0.0380 425	MED1/T CAP/UB E4B	3
G0:000 9314	respon se to radiat ion	6/43	421/16 672	0.0006 91344	0.0484 27142	0.0380 425	PPP1R1 B/CCL7 /GNA11 /MYC/E CT2/UB E4B	6
G0:005 0678	regula tion of epithe lial cell prolif eratio n	5/43	281/16 672	0.0007 48148	0.0484 27142	0.0380 425	MED1/P DCD10/ MYDGF/ MYC/KD F1	5
G0:000 3222	ventri cular trabec ula myocar dium morpho genesi s	2/43	16/166 72	0.0007 62048	0.0484 27142	0.0380 425	MED1/U BE4B	2
G0:006 0415	muscle tissue morpho genesi s	3/43	72/166 72	0.0008 41995	0.0484 27142	0.0380 425	MED1/T CAP/UB E4B	3
G0:000 7213	G-prot ein couple d acetyl	2/43	18/166 72	0.0009 68435	0.0484 27142	0.0380 425	GNA15/ GNA11	2

	cholin e recept or signal ing pathwa y							
G0:009 5500	acetyl cholin e recept or signal ing pathwa y	2/43	18/166 72	0.0009 68435	0.0484 27142	0.0380 425	GNA15/ GNA11	2
G0:190 3831	signal transd uction involv ed in cellul ar respon se to ammoni um ion	2/43	18/166 72	0.0009 68435	0.0484 27142	0.0380 425	GNA15/ GNA11	2
G0:190 5144	respon se to acetyl cholin e	2/43	18/166 72	0.0009 68435	0.0484 27142	0.0380 425	GNA15/ GNA11	2
G0:190 5145	cellul ar respon se to acetyl cholin e	2/43	18/166 72	0.0009 68435	0.0484 27142	0.0380 425	GNA15/ GNA11	2
G0:000 6367	transc ription initia	4/43	173/16 672	0.0010 07899	0.0484 27142	0.0380 425	MED1/M ED16/P OLR2E/ MED24	4

	tion from RNA polyme rase II promot er							
G0:004 8644	muscle organ morpho genesi s	3/43	78/166 72	0.0010 62553	0.0487 32561	0.0382 82425	MED1/T CAP/UB E4B	3
G0:004 5606	positi ve regula tion of epider mal cell differ entiat ion	2/43	20/166 72	0.0011 98702	0.0491 39845	0.0386 02372	MED1/K DF1	2
G0:190 1623	regula tion of lympho cyte chemot axis	2/43	20/166 72	0.0011 98702	0.0491 39845	0.0386 02372	CCL7/C CL4	2
G0:004 3410	positi ve regula tion of MAPK cascad e	6/43	471/16 672	0.0012 36736	0.0491 39845	0.0386 02372	CCL7/P DCD10/ PIK3R5 /GADD4 5B/MYD GF/CCL 4	6
G0:000 2573	myeloi d leukoc yte differ entiat ion	4/43	184/16 672	0.0012 6624	0.0491 39845	0.0386 02372	MED1/F STL3/M YC/SBN 02	4
G0:007 1242	cellul ar	2/43	21/166 72	0.0013 22715	0.0494 30352	0.0388 30583	GNA15/ GNA11	2

	respon se to ammoni um ion							
G0:006 0359	respon se to ammoni um ion	2/43	22/166 72	0.0014 52608	0.0523 45774	0.0411 20826	GNA15/ GNA11	2
G0:001 4706	striat ed muscle tissue develo pment	5/43	329/16 672	0.0015 10638	0.0525 59774	0.0412 88936	MED1/E EF2/TC AP/HMG 20B/UB E4B	5
G0:005 0878	regula tion of body fluid levels	6/43	495/16 672	0.0015 94166	0.0536 17128	0.0421 19553	MED1/P IK3R5/ GNA15/ GNA11/ HMG20B /KDF1	6
G0:005 0673	epithe lial cell prolif eratio n	5/43	336/16 672	0.0016 57253	0.0539 4091	0.0423 73904	MED1/P DCD10/ MYDGF/ MYC/KD F1	5
G0:006 0537	muscle tissue develo pment	5/43	343/16 672	0.0018 14111	0.0557 10777	0.0437 64243	MED1/E EF2/TC AP/HMG 20B/UB E4B	5
G0:000 7517	muscle organ develo pment	5/43	344/16 672	0.0018 3738	0.0557 10777	0.0437 64243	MED1/E EF2/TC AP/HMG 20B/UB E4B	5
G0:200 0403	positi ve regula tion of lympho cyte migrat ion	2/43	25/166 72	0.0018 77271	0.0557 10777	0.0437 64243	CCL7/C CL4	2

G0:000 7200	phospholipase C-activating G-protein coupled receptor signaling pathway	3/43	98/166 72	0.0020 49623	0.0590 87706	0.0464 17029	KISS1R /GNA15 /GNA11	3
G0:001 0837	regulation of keratinocyte proliferation	2/43	29/166 72	0.0025 24017	0.0707 42591	0.0555 72658	MED1/K DF1	2
G0:003 0224	monocyte differentiation	2/43	31/166 72	0.0028 81378	0.0745 46413	0.0585 60794	MED1/M YC	2
G0:006 0603	mammary gland duct morphogenesis	2/43	31/166 72	0.0028 81378	0.0745 46413	0.0585 60794	MED1/S OSTDC1	2
G0:190 3131	mononuclear cell differentiation	2/43	31/166 72	0.0028 81378	0.0745 46413	0.0585 60794	MED1/M YC	2
G0:004 5684	positive regulation of epider	2/43	32/166 72	0.0030 68454	0.0774 01745	0.0608 03833	MED1/K DF1	2

	mis develo pment							
G0:005 0680	negati ve regula tion of epithe lial cell prolif eratio n	3/43	115/16 672	0.0032 27682	0.0783 43773	0.0615 43853	MED1/P DCD10/ KDF1	3
G0:006 1384	heart trabec ula morpho genesi s	2/43	33/166 72	0.0032 61089	0.0783 43773	0.0615 43853	MED1/U BE4B	2
G0:004 2542	respon se to hydrog en peroxi de	3/43	119/16 672	0.0035 5404	0.0833 95955	0.0655 12653	PDCD10 /EEF2/ ECT2	3
G0:003 0518	intrac ellula r steroi d hormon e recept or signal ing pathwa y	3/43	123/16 672	0.0038 99928	0.0894 32444	0.0702 54687	MED1/M ED16/M ED24	3
G0:200 0401	regula tion of lympho cyte migrat ion	2/43	38/166 72	0.0043 06651	0.0933 23089	0.0733 11028	CCL7/C CL4	2



G0:007 1248	cellular response to metal ion	3/43	129/16672	0.004456151	0.093323089	0.073311028	MT1M/FSTL3/ECT2	3
G0:003 0049	muscle filament sliding	2/43	39/16672	0.004532043	0.093323089	0.073311028	TCAP/MYH8	2
G0:003 3275	actin-myosin filament sliding	2/43	39/16672	0.004532043	0.093323089	0.073311028	TCAP/MYH8	2
G0:004 3616	keratinocyte proliferation	2/43	39/16672	0.004532043	0.093323089	0.073311028	MED1/KDF1	2
G0:005 1302	regulation of cell division	3/43	132/16672	0.004751394	0.095883123	0.075322092	MYC/ECT2/KDF1	3

**S7 Table. The pathways KEGG pathways enriched by DRGs.**

Pathway ID	Description	Gene Ratio	BgRatio	pvalue	p.adjust	qvalue	geneID	Count
hsa04062	Chemokine signaling pathway	6/19	182/7240	4.80E-06	0.000240129	0.000240129	6356/6360/6362/6368/6355/6352	6
hsa04060	Cytokine-cytokine receptor interaction	6/19	270/7240	4.58E-05	0.001145446	0.001145446	6356/6360/6362/6368/6355/6352	6

	ction							
hsa05012	Parkinson's disease	2/19	142/7240	0.052536778	0.355317868	0.355317868	4711/6570	2
hsa05224	Breast cancer	2/19	144/7240	0.053865778	0.355317868	0.355317868	672/27006	2
hsa00514	Other types of O-glycan biosynthesis	1/19	22/7240	0.056250789	0.355317868	0.355317868	4242	1
hsa03010	Ribosome	2/19	154/7240	0.060690862	0.355317868	0.355317868	6209/6143	2
hsa04977	Vitamin digestion and absorption	1/19	24/7240	0.061213071	0.355317868	0.355317868	338	1
hsa04950	Maturity onset diabetes of the young	1/19	26/7240	0.066150627	0.355317868	0.355317868	6928	1
hsa04621	NOD-like receptor signaling pathway	2/19	168/7240	0.070723763	0.355317868	0.355317868	55669/6352	2
hsa04744	Phototransduction	1/19	28/7240	0.071063574	0.355317868	0.355317868	5957	1
hsa05310	Asthma	1/19	31/7240	0.078387105	0.356305023	0.356305023	6356	1
hsa05020	Prion disease	1/19	35/7240	0.088066759	0.362050403	0.362050403	6352	1

	es							
hsa03440	Homologous recombination	1/19	41/7240	0.102405834	0.362050403	0.362050403	672	1
hsa04975	Fat digestion and absorption	1/19	41/7240	0.102405834	0.362050403	0.362050403	338	1
hsa04330	Notch signaling pathway	1/19	48/7240	0.118864779	0.362050403	0.362050403	4242	1
hsa05030	Cocaine addiction	1/19	49/7240	0.121192583	0.362050403	0.362050403	6570	1
hsa03460	Fanconi anemia pathway	1/19	55/7240	0.135037528	0.362050403	0.362050403	672	1
hsa04721	Synaptic vesicle cycle	1/19	63/7240	0.153176258	0.362050403	0.362050403	6570	1
hsa04623	Cytosolic DNA-sensing pathway	1/19	64/7240	0.155418093	0.362050403	0.362050403	6352	1
hsa04137	Mitophagy - animal	1/19	65/7240	0.157654305	0.362050403	0.362050403	55669	1
hsa05031	Amphetamine addiction	1/19	68/7240	0.164329334	0.362050403	0.362050403	6570	1
hsa05120	Epithelial	1/19	68/7240	0.164329334	0.362050403	0.362050403	6352	1

	cell signaling in Helicobacter pylori infection							
hsa05218	Melanoma	1/19	69/7240	0.166543185	0.362050403	0.362050403	27006	1
hsa01524	Platinum drug resistance	1/19	73/7240	0.175343153	0.365298235	0.365298235	672	1
hsa04911	Insulin secretion	1/19	85/7240	0.201217945	0.40103239	0.40103239	27094	1
hsa05323	Rheumatoid arthritis	1/19	90/7240	0.211770473	0.40103239	0.40103239	6352	1
hsa04657	IL-17 signaling pathway	1/19	93/7240	0.218038452	0.40103239	0.40103239	6356	1
hsa04151	PI3K-Akt signaling pathway	2/19	342/7240	0.225536145	0.40103239	0.40103239	672/27006	2
hsa05142	Chagas disease (American trypanosomiasis)	1/19	102/7240	0.236560296	0.40103239	0.40103239	6352	1
hsa04620	Toll-like receptor	1/19	104/7240	0.240619434	0.40103239	0.40103239	6352	1

	or signal ing pathwa y							
hsa046 68	TNF signal ing pathwa y	1/19	108/72 40	0.2486 76451	0.4010 91051	0.4010 91051	6352	1
hsa047 26	Seroto nergic synaps e	1/19	113/72 40	0.2586 33864	0.4041 15412	0.4041 15412	6570	1
hsa042 70	Vascul ar smooth muscle contra ction	1/19	121/72 40	0.2743 06115	0.4156 15326	0.4156 15326	27094	1
hsa047 28	Dopami nergic synaps e	1/19	130/72 40	0.2915 62105	0.4232 13772	0.4232 13772	6570	1
hsa001 90	Oxidat ive phosph orylat ion	1/19	133/72 40	0.2972 27196	0.4232 13772	0.4232 13772	4711	1
hsa041 20	Ubiqui tin mediat ed proteo lysis	1/19	137/72 40	0.3047 13916	0.4232 13772	0.4232 13772	672	1
hsa049 32	Non-al coholi c fatty liver diseas e (NAFLD )	1/19	149/72 40	0.3267 23345	0.4415 18034	0.4415 18034	4711	1
hsa040	cGMP-P	1/19	163/72	0.3515	0.4497	0.4497	27094	1

22	KG signaling pathway		40	6672	28714	28714		
hsa04530	Tight junction	1/19	170/72 40	0.3636 60278	0.4497 28714	0.4497 28714	4620	1
hsa05010	Alzheimer's disease	1/19	171/72 40	0.3653 70385	0.4497 28714	0.4497 28714	4711	1
hsa05164	Influenza A	1/19	173/72 40	0.3687 77545	0.4497 28714	0.4497 28714	6352	1
hsa05034	Alcoholism	1/19	180/72 40	0.3805 66645	0.4521 62082	0.4521 62082	6570	1
hsa05168	Herpes simplex infection	1/19	185/72 40	0.3888 59391	0.4521 62082	0.4521 62082	6352	1
hsa05016	Huntington's disease	1/19	193/72 40	0.4019 09386	0.4567 15212	0.4567 15212	4711	1
hsa04015	Rap1 signaling pathway	1/19	210/72 40	0.4287 69386	0.4694 05614	0.4694 05614	27006	1
hsa04810	Regulation of actin cytoskeleton	1/19	212/72 40	0.4318 53165	0.4694 05614	0.4694 05614	27006	1
hsa04014	Ras signaling pathway	1/19	227/72 40	0.4544 83883	0.4834 93493	0.4834 93493	27006	1
hsa04010	MAPK signaling pathway	1/19	255/72 40	0.4944 61866	0.5150 64444	0.5150 64444	27006	1

	y							
hsa05206	MicroRNAs in cancer	1/19	299/7240	0.551726105	0.562985821	0.562985821	672	1
hsa05200	Pathways in cancer	1/19	395/7240	0.656070145	0.656070145	0.656070145	27006	1

**S8 Table. The pathways KEGG pathways enriched by DSGs.**

Pathway ID	Description	Gene Ratio	BgRatio	pvalue	p.adjust	qvalue	geneID	Count
hsa04919	Thyroid hormone signaling pathway	4/23	116/7240	0.000437833	0.032837463	0.031339614	5469/10025/9862/4609	4
hsa04210	Apoptosis	3/23	138/7240	0.009077066	0.340389971	0.324863411	4616/8743/84823	3
hsa04623	Cytosolic DNA-sensing pathway	2/23	64/7240	0.017271045	0.431776126	0.412081074	5434/6351	2
hsa04064	NF-kappa B signaling pathway	2/23	95/7240	0.036047657	0.445087718	0.424785471	4616/6351	2
hsa05146	Amoebiasis	2/23	96/7240	0.036744397	0.445087718	0.424785471	2769/2767	2
hsa05142	Chagas disease (American trypanosomiasis)	2/23	102/7240	0.041034096	0.445087718	0.424785471	2769/2767	2

	sis)							
hsa04725	Cholinergic synapse	2/23	112/7240	0.048583264	0.445087718	0.424785471	23533/2767	2
hsa04060	Cytokine-cytokine receptor interaction	3/23	270/7240	0.052369957	0.445087718	0.424785471	6354/6351/8743	3
hsa04110	Cell cycle	2/23	124/7240	0.058258204	0.445087718	0.424785471	4616/4609	2
hsa04068	FoxO signaling pathway	2/23	132/7240	0.065054322	0.445087718	0.424785471	4616/8743	2
hsa04120	Ubiquitin mediated proteolysis	2/23	137/7240	0.069433695	0.445087718	0.424785471	997/10277	2
hsa04310	Wnt signaling pathway	2/23	143/7240	0.074816192	0.445087718	0.424785471	4609/79718	2
hsa04921	Oxytocin signaling pathway	2/23	153/7240	0.084078467	0.445087718	0.424785471	23533/1938	2
hsa05216	Thyroid cancer	1/23	29/7240	0.088307851	0.445087718	0.424785471	4609	1
hsa04022	cGMP-PKG signaling pathway	2/23	163/7240	0.093679605	0.445087718	0.424785471	23533/2767	2



	y							
hsa03020	RNA polymerase	1/23	32/720	0.09700498	0.445087718	0.424785471	5434	1
hsa05202	Transcriptional misregulation in cancer	2/23	180/7240	0.110700191	0.445087718	0.424785471	4609/8444	2
hsa04020	Calcium signaling pathway	2/23	182/7240	0.112755555	0.445087718	0.424785471	2769/2767	2
hsa04062	Chemokine signaling pathway	2/23	182/7240	0.112755555	0.445087718	0.424785471	6354/6351	2
hsa05219	Bladder cancer	1/23	41/7240	0.122622775	0.459835406	0.438860458	4609	1
hsa05169	Epstein-Barr virus infection	2/23	203/7240	0.134928902	0.459926404	0.438947305	5434/4609	2
hsa05030	Cocaine addiction	1/23	49/7240	0.144809258	0.459926404	0.438947305	84152	1
hsa05213	Endometrial cancer	1/23	50/7240	0.147544536	0.459926404	0.438947305	4609	1
hsa04978	Mineral absorption	1/23	51/7240	0.150271445	0.459926404	0.438947305	4499	1
hsa05221	Acute myeloid	1/23	55/7240	0.161095875	0.459926404	0.438947305	4609	1

	d leukem ia							
hsa003 10	Lysine degrad ation	1/23	59/724 0	0.1717 88338	0.4599 26404	0.4389 47305	84444	1
hsa047 30	Long-t erm depres sion	1/23	60/724 0	0.1744 41014	0.4599 26404	0.4389 47305	2767	1
hsa052 10	Colore ctal cancer	1/23	60/724 0	0.1744 41014	0.4599 26404	0.4389 47305	4609	1
hsa052 30	Centra l carbon metabo lism in cancer	1/23	65/724 0	0.1875 8295	0.4599 26404	0.4389 47305	4609	1
hsa040 10	MAPK signal ing pathwa y	2/23	255/72 40	0.1934 19416	0.4599 26404	0.4389 47305	4616/4 609	2
hsa050 31	Amphet amine addict ion	1/23	68/724 0	0.1953 71806	0.4599 26404	0.4389 47305	84152	1
hsa041 15	p53 signal ing pathwa y	1/23	69/724 0	0.1979 5218	0.4599 26404	0.4389 47305	4616	1
hsa052 20	Chroni c myeloi d leukem ia	1/23	71/724 0	0.2030 89204	0.4599 26404	0.4389 47305	4609	1
hsa049 25	Aldost erone synthe sis and secret	1/23	82/724 0	0.2307 8504	0.4599 26404	0.4389 47305	2767	1

	ion							
hsa04350	TGF-beta signaling pathway	1/23	84/7240	0.235720707	0.459926404	0.438947305	4609	1
hsa05222	Small cell lung cancer	1/23	84/7240	0.235720707	0.459926404	0.438947305	4609	1
hsa04911	Insulin secretion	1/23	85/7240	0.238177166	0.459926404	0.438947305	2767	1
hsa04012	ErbB signaling pathway	1/23	86/7240	0.240626073	0.459926404	0.438947305	4609	1
hsa05132	Salmonella infection	1/23	86/7240	0.240626073	0.459926404	0.438947305	6351	1
hsa04540	Gap junction	1/23	88/7240	0.245501315	0.459926404	0.438947305	2767	1
hsa04912	GnRH signaling pathway	1/23	92/7240	0.255162134	0.459926404	0.438947305	2767	1
hsa04657	IL-17 signaling pathway	1/23	93/7240	0.257558786	0.459926404	0.438947305	6354	1
hsa01522	Endocrine resistance	1/23	96/7240	0.264704566	0.460504114	0.439498663	5469	1
hsa04620	Toll-like recept	1/23	104/7240	0.283439793	0.460504114	0.439498663	6351	1

	or signaling pathway							
hsa00240	Pyrimidine metabolism	1/23	105/7240	0.285749334	0.460504114	0.439498663	5434	1
hsa04151	PI3K-Akt signaling pathway	2/23	342/7240	0.296744965	0.460504114	0.439498663	23533/4609	2
hsa05145	Toxoplasmosis	1/23	113/7240	0.303971052	0.460504114	0.439498663	23533	1
hsa04152	AMPK signaling pathway	1/23	121/7240	0.32174762	0.460504114	0.439498663	1938	1
hsa04270	Vascular smooth muscle contraction	1/23	121/7240	0.32174762	0.460504114	0.439498663	2767	1
hsa04611	Platelet activation	1/23	123/7240	0.32612343	0.460504114	0.439498663	23533	1
hsa04728	Dopaminergic synapse	1/23	130/7240	0.341227097	0.460504114	0.439498663	84152	1
hsa04650	Natural killer cell mediated cytoto	1/23	133/7240	0.347600486	0.460504114	0.439498663	8743	1

	xicity							
hsa03040	Spliceosome	1/23	134/7240	0.349711812	0.460504114	0.439498663	8175	1
hsa05162	Measles	1/23	134/7240	0.349711812	0.460504114	0.439498663	8743	1
hsa04371	Apelin signaling pathway	1/23	138/7240	0.35809194	0.460504114	0.439498663	23533	1
hsa05200	Pathways in cancer	2/23	395/7240	0.359727345	0.460504114	0.439498663	2767/4609	2
hsa04550	Signaling pathways regulating pluripotency of stem cells	1/23	139/7240	0.360170774	0.460504114	0.439498663	4609	1
hsa04261	Adrenergic signaling in cardiomyocytes	1/23	144/7240	0.370468721	0.460504114	0.439498663	23533	1
hsa05161	Hepatitis B	1/23	144/7240	0.370468721	0.460504114	0.439498663	4609	1
hsa05224	Breast cancer	1/23	144/7240	0.370468721	0.460504114	0.439498663	4609	1
hsa04072	Phospholipase D signaling pathway	1/23	146/7240	0.374543346	0.460504114	0.439498663	23533	1
hsa04390	Hippo signaling	1/23	154/7240	0.390591002	0.4696916	0.448267071	4609	1

	pathway							
hsa04630	Jak-STAT signaling pathway	1/23	156/7240	0.394540944	0.4696916	0.448267071	4609	1
hsa04141	Protein processing in endoplasmic reticulum	1/23	166/7240	0.413926109	0.482310396	0.460310273	10277	1
hsa04530	Tight junction	1/23	170/7240	0.421512726	0.482310396	0.460310273	4626	1
hsa05164	Influenza A	1/23	173/7240	0.427140947	0.482310396	0.460310273	8743	1
hsa00230	Purine metabolism	1/23	175/7240	0.430863954	0.482310396	0.460310273	5434	1
hsa05034	Alcoholism	1/23	180/7240	0.44007049	0.485371864	0.463232095	84152	1
hsa05168	Herpes simplex infection	1/23	185/7240	0.449134473	0.488189645	0.465921345	997	1
hsa05016	Huntington's disease	1/23	193/7240	0.463345587	0.4964417	0.473796991	5434	1
hsa04024	cAMP signaling pathway	1/23	198/7240	0.472048725	0.498643019	0.475897899	84152	1
hsa05205	Proteoglycans in cancer	1/23	203/7240	0.480616762	0.50064246	0.477806137	4609	1

hsa05166	HTLV-I infection	1/23	256/7240	0.563632079	0.579074054	0.55266015	4609	1
hsa04080	Neuroactive ligand-receptor interaction	1/23	278/7240	0.594222349	0.602252381	0.57478122	84634	1
hsa05206	MicroRNAs in cancer	1/23	299/7240	0.621500896	0.621500896	0.593151732	4609	1